comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.

Lloyd P., Hong A., Furrer MA., Lee EWY., Dev HS., Coret MH., Adshead JM., Baldwin P., Knight R., Shamash J., Alifrangis C., Stoneham S., Mazhar D., Wong H., Warren A., Tran B., Lawrentschuk N., Neal DE., Thomas BC.

PURPOSE: To describe and compare differences in peri-operative outcomes of robot-assisted (RA-RPLND) and open (O-RPLND) retroperitoneal lymph node dissection performed by a single surgeon where chemotherapy is the standard initial treatment for Stage 2 or greater non-seminomatous germ cell tumour. METHODS: Review of a prospective database of all RA-RPLNDs (28 patients) and O-RPLNDs (72 patients) performed by a single surgeon from 2014 to 2020. Peri-operative outcomes were compared for patients having RA-RPLND to all O-RPLNDs and a matched cohort of patients having O-RPLND (20 patients). Further comparison was performed between all patients in the RA-RPLND group (21 patients) and matched O-RPLND group (18 patients) who had previous chemotherapy. RA-RPLND was performed for patients suitable for a unilateral template dissection. O-RPLND was performed prior to the introduction of RA-RPLND and for patients not suitable for RA-RPLND after its introduction. RESULTS: RA-RPLND showed improved peri-operative outcomes compared to the matched cohort of O-RPLND-median blood loss (50 versus 400 ml, p < 0.00001), operative duration (150 versus 195 min, p = 0.023) length-of-stay (1 versus 5 days, p < 0.00001) and anejaculation (0 versus 4, p = 0.0249). There was no statistical difference in complication rates. RA-RPLND had lower median lymph node yields although not significant (9 versus 13, p = 0.070). These improved peri-operative outcomes were also seen in the post-chemotherapy RA-RPLND versus O-RPLND analysis. There were no tumour recurrences seen in either group with median follow-up of 36 months and 60 months, respectively. CONCLUSIONS: Post-chemotherapy RA-RPLND may have decreased blood loss, operative duration, hospital length-of-stay and anejaculation rates in selected cases and should, therefore, be considered in selected patients. Differences in oncological outcomes require longer term follow-up.

DOI

10.1007/s00345-021-03832-0

Type

Journal article

Publication Date

2022-01-01T00:00:00+00:00

Volume

40

Pages

119 - 126

Total pages

7

Keywords

Retroperitoneal lymph node dissection, Robotic surgery, Testicular cancer, Combined Modality Therapy, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Neoplasms, Germ Cell and Embryonal, Retroperitoneal Space, Robotic Surgical Procedures, Testicular Neoplasms, Treatment Outcome

Permalink More information Close